Skip to Main Content

Paper Details

Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
Neuro Oncol
0
2023
patients, recurrent glioblastoma
Author NameAffiliation
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonUniversity of California Los Angeles
Benjamin M EllingsonUniversity of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Neuro-Oncology Program, University of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers
Benjamin M Ellingsonuniversity of california los angeles Neuro-Oncology Program, University of California Los Angeles
Benjamin M EllingsonUniversity of California Los Angeles
Benjamin M EllingsonUniversity of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School
Timothy F Cloughesyuniversity of california los angeles Neuro-Oncology Program, University of California Los Angeles
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
Timothy F Cloughesyuniversity of california los angeles Neuro-Oncology Program, University of California Los Angeles
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 15

Datasets